Genetic influences of angiotensin-converting enzyme inhibitor response: An opportunity for personalizing therapy?

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 8, 2012, Pages 1001-1009

  Brugts, Jasper J ^a   Simoons, Maarten L ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibitor; aldosterone; angiotensin; coronary artery disease; gene; hypertension; pharmacogenetic; renin

Indexed keywords

BRADYKININ; BRADYKININ B2 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; PERINDOPRIL; RAMIPRIL; TRANDOLAPRIL;

AFRICAN AMERICAN; ANTIHYPERTENSIVE THERAPY; ARTERIOLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; COUGHING; DNA POLYMORPHISM; DRUG TARGETING; FOLLOW UP; GENE DELETION; GENE INSERTION; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RISK; HEART ARREST; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTOR VARIABLE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SODIUM RETENTION; TREATMENT RESPONSE; VASODILATATION; WATER RETENTION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CORONARY ARTERY DISEASE; DRUG RESISTANCE; GENETIC ASSOCIATION STUDIES; HUMANS; HYPERTENSION; INDIVIDUALIZED MEDICINE; PEPTIDYL-DIPEPTIDASE A; PHARMACOGENETICS;

EID: 84867082132     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.83     Document Type: Review

References (46)

1. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327(10), 669-677 (1992).
2. No authors listed. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 325, 293-302 (1991).
3. No authors listed. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet 342, 821-828 (1993).
4. Torp-Pedersen C, Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet 354(9172), 9-12 (1999).
5. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensinconverting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
6. Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351, 2058-2068 (2004).
7. Fox KM; The European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomized, double-blind, placebo controlled, multicentre trial (the EUROPA study). Lancet 362, 782-788 (2003).
8. Brugts JJ, Ferrari R, Simoons ML. Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev. Cardiovasc. Ther. 7(4), 345-360 (2009).
9. Fox K, Garcia MA, Ardissino D et al.; The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.Guidelines on the management of stable angina pectoris. Eur. Heart J. 27, 1341-1381 (2006).
10. Wood D, DeBacker G, Faergam O et al. Prevention of coronary disease in clinical practice: recommendation of the second joint task force of European and other societies on coronary prevention. Atherosclerosis 140, 99-270 (1998).
11. Gibbons RJ, Abrams J, Chatterjee K et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina - summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients with Chronic Stable Angina). J. Am. Coll. Cardiol. 41, 159-168 (2003).
12. Pellacani A, Brunner HR, Nussberger J. Plasma kinins increase after angiotensin enzyme inhibition in human subjects. Clin. Sci. 87, 567-574 (1994).
13. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev. Cardiovasc. Ther. 3(1), 15-29 (2005).
14. Brugts JJ, den Uil CA, Danser AH, Boersma E. The renin-angiotensin- aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 112(4), 303-312 (2009).
15. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 368(9535), 581-588 (2006).
16. Deckers JW, Goedhart DM, Boersma E et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur. Heart J. 27(7), 796-801 (2006).
17. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Arch. Intern. Med. 165(22), 2659-2665 (2005).
18. Solomon SD, Rice MM, A Jablonski K et al.; Prevention of Events with ACE Inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensinconverting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE Inhibition (PEACE) trial. Circulation 114(1), 26-31 (2006).
19. Brugts JJ, Boersma E, Chonchol M et al.; EUROPA Investigators. The cardioprotective effects of the angiotensinconverting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J. Am. Coll. Cardiol. 50(22), 2148-2155 (2007).
20. Brugts JJ, Ninomiya T, Boersma E et al. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur. Heart J. 30(11), 1385-1394 (2009).
21. Danser AH, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur. J. Pharmacol. 410(2-3), 303-316 (2000).
22. Brugts JJ, Danser AH, de Maat MP et al. Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr. Opin. Cardiol. 23(4), 296-301 (2008).
23. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
24. Tiret L, Rigat B, Visvikis S et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am. J. Hum. Genet. 51(1), 197-205 (1992).
25. Keavney B, McKenzie C, Parish S et al. Large-scale test of hypothesised associations between the angiotensinconverting- enzyme insertion/deletion polymorphism and myocardial infarction in about 5000 cases and 6000 controls. International Studies of Infarct Survival (ISIS) Collaborators. Lancet 355(9202), 434-442 (2000).
26. Agerholm-Larsen B, Nordestgaard BG, Tybjærg-Hansen A. ACE gene polymorphism in cardiovascular disease: meta-analyses of small and large studies in whites. Arterioscler. Thromb. Vasc. Biol. 20, 484-492 (2000).
27. Arnett DK, Davis BR, Ford CE et al. Pharmacogenetic association of the angiotensin-converting enzyme insertion/ deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 111(25), 3374-3383 (2005).
28. Harrap SB, Tzourio C, Cambien F et al.; PROGRESS Collaborative Group. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 42(3), 297-303 (2003).
29. Bhatnagar V, O'Conner DT, Schork NJ et al. Angiotensin-converting enzyme gene polymorphism predicts the time-course of BP response to ACE inhibition in the AASK trial. J. Hypertens. 25(10), 2082-2092 (2007).
30. Su X, Lee L, Li X et al. Association between angiotensinogen, angiotensin II receptor genes, and blood pressure response to an angiotensin-converting enzyme inhibitor. Circulation 115, 725-732 (2007).
31. Brugts JJ, de Maat MP, Boersma E et al.; EUROPA-PERGENE investigators. The rationale and design of the Perindopril Genetic Association Study (PERGENE): a pharmacogenetic analysis of angiotensinconverting enzyme inhibitor therapy in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 23(2), 171-181 (2009).
32. Brugts JJ, Isaacs A, Boersma E et al. Genetic determinants of treatment benefit of the angiotensin-converting enzymeinhibitor perindopril in patients with stable coronary artery disease. Eur. Heart J. 31(15), 1854-1864 (2010).
33. Brugts JJ, Isaacs A, de Maat MP et al. A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin- converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. J. Hypertens. 29(3), 509-519 (2011).
34. Brugts JJ, Boersma E, Simoons ML. Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. Pharmacogenomics 11(8), 1115-1126 (2010).
35. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur. J. Epidemiol. 7(4), 403-422 (1991).
36. Brugts JJ, de Maat MP, Danser AH, Boersma E, Simoons ML. Individualised therapy of angiotensin converting enzyme (ACE) inhibitors in stable coronary artery disease: overview of the primary results of the Perindopril Genetic Association (PERGENE) Study. Neth. Heart J. 20(1), 24-32 (2012).
37. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensinconverting- enzyme inhibitor in normotensive and hypertensive subjects. N. Engl. J. Med. 339(18), 1285-1292 (1998).
38. Xu J, Carretero OA, Shesely EG et al. The kinin B1 receptor contributes to the cardioprotective effect of angiotensinconverting enzyme inhibitors andangiotensin receptor blockers in mice. Exp. Physiol. 94(3), 322-329 (2009).
39. Marin-Castaño ME, Schanstra JP, Neau E et al. Induction of functional bradykinin B(1)-receptors in normotensive rats and mice under chronic angiotensin-converting enzyme inhibitor treatment. Circulation 105(5), 627-632 (2002).
40. Ignjatovic T, Tan F, Brovkovych V, Skidgel RA, Erdös EG. Novel mode of action of angiotensin I converting enzyme inhibitors: direct activation of bradykinin B1 receptor. J. Biol. Chem. 277(19), 16847-16852 (2002).
41. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdös EG. Kinin B1 receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol. Pharmacol. 66(5), 1310-1316 (2004).
42. Fortin JP, Gobeil F Jr, Adam A, Regoli D, Marceau F. Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor?. Am. J. Physiol. Heart Circ. Physiol. 285(1), H277-H282 (2003).
43. Su JB, Hoüel R, Héloire F, Barbe F, et al. Stimulation of bradykinin B1 receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs. Circulation 101, 1848-1853 (2000).
44. Mas S, Gassò P, Alvarez S et al. Pharmacogenetic predictors of angiotensinconverting enzyme inhibitor-induced cough: the role of ACE, ABO, and BDKRB2 genes. Pharmacogenet. Genomics 21(9), 531-538 (2011).
45. Austinat M, Braeuninger S, Pesquero JB et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 40(1), 285-293 (2009).
46. Petrovic D, Peterlin B. Pharmacogenomic considerations of the insertion/deletion gene polymorphism of the angiotensin I-converting enzyme and coronary artery disease. Curr. Vasc. Pharmacol. 2(3), 271-279 (2004).